Sunday, March 7, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Funding for Preclinical Development of Countermeasures Against Select Pathogens

by Global Biodefense Staff
June 8, 2020
Cutting Edge Chemical and Biological Defense Science: Hot Topics at CBD S&T 2019

Credit: Global Biodefense

A new funding opportunity from the National Institute of Allergy and Infectious Diseases (NIAID), Partnerships for Countermeasures Against Select Pathogens, will support preclinical development of lead candidate therapeutics, vaccines, and related countermeasures against select emerging infectious diseases and pathogens, including coronavirus.

The call for proposals encourages a broad array of preclinical activities including lead optimization, efficacy testing, safety evaluation, stability testing, manufacturing, scale-up, and investigational new drug-enabling activities.

Therapeutics

The funding encourages preclinical development of candidate therapeutics against select pathogens (antimicrobial resistant bacteria or fungi listed in CDC’s report Antibiotic Resistance Threats in the United States, 2019 or emerging viral pathogens (listed in NIAID Emerging Infectious Diseases and Pathogens). This includes immune-based and host-targeted forms, with emphasis on broad-spectrum therapeutics and those targeting pathogens for which no standard clinical treatment exists or for which drug resistance poses a significant public health concern.

Therapeutics of interest include small molecules, biopharmaceuticals, nucleic acids, or peptides to be used as monotherapy or in combination, or as adjunctive therapy, with other drugs.

Vaccines

This opportunity supports research developing candidate vaccines (including immunoprophylactics) focusing on multivalent/universal forms or vaccines targeting select emerging pathogens—antimicrobial-resistant bacteria or fungi or viral pathogens.

Industry Partner

Applications from academic institutions must include substantive investment from an industry participant to facilitate appropriate and validated product development activities. The industry partner can be a large or small, domestic or foreign, pharmaceutical, biotechnology, bioengineering, or chemical company, or a related non-profit entity with an established track record in product development. The FOA describes activities and contributions that would constitute appropriate investment by the industrial partner.

Through this initiative, NIAID plans to fund 10 to 15 awards. Applications are due on June 29, 2020.

Tags: Antibiotic ResistanceDrug DevelopmentEditor PickRequest for ProposalsSelect AgentsVaccines

Related Posts

Medical Countermeasure Development
Funding News

2021 BAA for Development of Medical Countermeasures for Biological Threats

March 2, 2021
UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)
Funding News

UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

March 2, 2021
New Coronavirus Variant: Here Is What Scientists Know About B1525
Biosurveillance

New Coronavirus Variant: Here Is What Scientists Know About B1525

March 2, 2021
How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?
Medical Countermeasures

How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

March 2, 2021
Load More

Latest News

Medical Countermeasure Development

2021 BAA for Development of Medical Countermeasures for Biological Threats

March 2, 2021
UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

March 2, 2021
New Coronavirus Variant: Here Is What Scientists Know About B1525

New Coronavirus Variant: Here Is What Scientists Know About B1525

March 2, 2021
How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

March 2, 2021

Upcoming Events

Mar 7
Virtual Event
March 6 - March 10

CROI 2021 – Conference on Retroviruses and Opportunistic Infections

Mar 8
Virtual Event
March 8 - March 10

Quantum-Enabled Sensing and Imaging for Biology

Mar 8
Virtual Event
2:00 pm - 3:30 pm

TRB Webinar: Visualizing Effects of COVID-19 on Transportation: A One-Year Retrospective

Mar 9
Virtual Event
March 9 - March 11

The Current Global Governance Landscape for Influenza

Mar 9
Virtual Event
March 9 @ 11:00 am - March 10 @ 4:00 pm EST

Rapid Response by Laboratory Animal Research Institutions During the COVID-19 Pandemic

View More
Tweets by GlobalBioD

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe

© 2021 Stemar Media Group LLC